What's Happening?
Quest Diagnostics has launched an advanced pharmacogenomics (PGx) testing service, positioning itself as a leader in precision medicine. The service analyzes genetic data to optimize drug therapies, addressing unmet clinical needs. Quest's initiative aligns with the growing PGx market, projected to reach $20.8 billion by 2032, and aims to enhance clinical decision-making across various medical specialties.
Why It's Important?
Quest Diagnostics' entry into the pharmacogenomics market represents a significant advancement in personalized medicine. By providing genetic insights for drug therapy optimization, Quest is poised to impact patient care and treatment outcomes. This development could drive innovation in the healthcare industry, influencing how medical professionals approach drug prescriptions and patient management.
